Cryptosporidium parvum phosphatidylinositol 4-kinase (CpPI4K) (CpPI4K)

Cryptosporidium parvum phosphatidylinositol 4-kinase (CpPI4K) is a vital enzyme for the survival and replication of the protozoan parasite Cryptosporidium parvum, which causes severe diarrheal disease (Manjunatha et al., 2017, Nature). The enzyme is responsible for producing phosphatidylinositol 4-phosphate (PI4P), a lipid essential for intracellular membrane trafficking and the maintenance of the parasite's structural integrity (Umehara et al., 2021, Communications Biology). CpPI4K is considered a validated therapeutic target because its inhibition effectively halts the parasite's life cycle during the intracellular stage (Nader et al., 2023, ACS Infectious Diseases). Small molecule inhibitors, such as the imidazopyrazine KDU731, have shown significant efficacy in clearing infections in bovine and murine models by selectively targeting the parasite's kinase over human isoforms (Manjunatha et al., 2017, Nature). This selectivity is crucial for minimizing host toxicity, as human PI4K enzymes are involved in essential cellular processes like signal transduction and vesicular transport (Jadhav et al., 2017, Journal of Medicinal Chemistry). Consequently, CpPI4K represents a promising focal point for the development of new treatments for cryptosporidiosis, particularly in vulnerable populations like children and HIV-positive patients.

Other names

PI4KPhosphatidylinositol 4-kinaseCpPI4KPIK4Phosphatidylinositol 4-kinase type III alpha

Inhibition of phosphatidylinositol 4-kinase activity, leading to disruption of intracellular membrane trafficking and inhibition of parasite growth and development.